Pfizer's COVID-19 vaccine sales have plummeted by 25% as the fall vaccination season unfolds, signaling a worrying trend for the pharmaceutical giant.
The sharp decline follows new guidance from the CDC that significantly narrows recommendations on who should receive the Comirnaty vaccine.
In the third quarter of 2025, the company reported a 7% drop in revenue compared to the same period the previous year, amplifying concerns about the vaccine's market performance.
The sluggish start to the fall vaccination campaign underscores the challenges Pfizer faces in generating public interest and trust in its product.
Recent federal regulatory decisions directly impact vaccine uptake, demonstrating the delicate interplay between health recommendations and consumer behavior in the fight against COVID-19.
As policymakers navigate an evolving public health landscape, the implications of these changes extend beyond Pfizer, reflecting broader struggles in vaccine acceptance and administration efforts.
7
